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Abstract Peripheral neuropathy is a common toxicity
associated with tubulin-targeted chemotherapeutic agents.
This Phase II study compares the incidence and severity of
neuropathy associated with eribulin mesylate or ixabepi-
lone in metastatic breast cancer (MBC). The primary
objective was to assess the incidence of neuropathy; the
study was designed to detect a difference in neuropathy
rate of 35 % for eribulin versus 63 % for ixabepilone (odds
ratio 0.316, 80 % power, 0.05 two-sided significance
level). Eligibility criteria included: MBC; prior taxane
therapy; at least one chemotherapy for advanced disease;
no or minimal pre-existing neuropathy (Grade 0 or 1). The
intent-to-treat population comprised 104 patients random-
ized (1:1) to eribulin mesylate (1.4 mg/m2, 2–5 min
intravenous on days 1 and 8) or ixabepilone (40 mg/m2,
3 h intravenous on day 1) on a 21-day cycle. 101 patients
in the safety population received a median of 5.0 eribulin
and 3.5 ixabepilone cycles. Incidence of neuropathy (any
grade) was 33.3 and 48.0 %, and peripheral neuropathy
was 31.4 and 44.0 % for eribulin and ixabepilone,
respectively. After controlling for pre-existing neuropathy
and number of prior chemotherapies, these differences
were not significant. Compared with ixabepilone, fewer
patients receiving eribulin discontinued treatment due to
neuropathy (3.9 vs. 18.0 %) or adverse events (AEs) in
general (11.8 vs. 32.0 %). Time to onset of neuropathy was
35.9 weeks for eribulin and 11.6 weeks for ixabepilone,
and time to resolution was 48 versus 10 weeks, respec-
tively; other AEs were comparable. Objective responses
were 15.4 versus 5.8 % and clinical benefit rates were 26.9
versus 19.2 %. In conclusion, after controlling for pre-
existing neuropathy and number of prior chemotherapies,
the differences in the incidence of neuropathy with eribulin
and ixabepilone were not statistically significant. Onset of
neuropathy tended to occur later with eribulin and resolve
later.
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CTCAE Common Terminology Criteria for Adverse
Events
DCR Disease control rate
ECOG Eastern Cooperative Oncology Group
EMBRACE Eisai Metastatic Breast Cancer Study
Assessing Physician’s Choice Versus E7389
FISH Fluorescence in situ hybridization
HER2 Human epidermal growth factor receptor 2
HR Hazard ratio
MBC Metastatic breast cancer
MedDRA Medical Dictionary for Regulatory Activities






PNQ Patient-reported neurotoxicity questionnaire
PR Partial response
SD Stable disease
TPC Treatment of physician’s choice
VPT Vibration perception threshold
Introduction
Eribulin mesylate (Halaven, INNM: eribulin mesilate,
E7389), a non-taxane microtubule dynamics inhibitor, is a
structurally simplified, synthetic analog of the natural
product Halichondrin B, isolated from the marine sponge
Halichondria okadai [1, 2]. By predominantly binding to
high affinity sites on the growing plus (?) ends of microtu-
bules, eribulin inhibits microtubule polymerization without
affecting depolymerization, which in turn induces irrevers-
ible mitotic block at G2-M phase and apoptosis [1–6]. This
mechanism of action is distinct from most other tubulin-
targeting chemotherapeutic agents currently in clinical use,
including taxanes, vinorelbine, and epothilones [3, 5].
In the randomized Phase III Eisai Metastatic Breast Cancer
Study Assessing Physician’s Choice Versus E7389
(EMBRACE) trial, which involved patients with heavily pre-
treated locally recurrent or metastatic breast cancer (MBC),
eribulin was compared with treatment of physician’s choice
(TPC) [7]. Patients had received a median of four previous
chemotherapy regimens including an anthracycline and a
taxane. Patients who received eribulin mesylate (1.4 mg/m2,
days 1 and 8 of a 21-day cycle) exhibited a significant
improvement in median overall survival (OS) compared with
TPC (13.1 vs. 10.6 months; hazard ratio [HR] 0.81; 95 %
confidence interval [CI] 0.66–0.99; p = 0.041). An updated
analysis of OS requested by regulatory authorities confirmed
the significant increase in OS for eribulin compared with TPC
(13.2 vs. 10.5 months; HR 0.81; 95 % CI 0.67–0.96; nominal
p = 0.014). This was the first Phase III monotherapy study to
meet its primary endpoint of prolonged OS in this patient
population. These results contributed in part to the Food and
Drug Administration’s approval of eribulin mesylate for
treatment of patients with MBC who have previously received
at least two chemotherapies for the treatment of metastatic
disease and an anthracycline and a taxane in either the adju-
vant or metastatic setting [8].
Peripheral neuropathy (PN) is a common toxicity asso-
ciated with chemotherapy agents which target microtubules.
It can also be a treatment-limiting factor for patients with
heavily pre-treated MBC [9], and have a significant impact
on patients’ routine activities, functions, and behavior [10].
In EMBRACE, 35 % of patients treated with eribulin
experienced PN (all grades), with 8 % and\1 % reporting
Grade 3 and 4 PN, respectively [7]. For patients in the TPC
arm, total incidence of PN was 16 % (Grade 3, 2 %; no Grade
4 events) [7]. In two Phase II studies of eribulin in patients
who had previously received an anthracycline and a taxane
[11] or an anthracycline, a taxane, and capecitabine [12],
incidences of PN were 26 % (Grade 1/2) and 5–7 % (Grade
3), with no Grade 4 events reported in either study.
Ixabepilone is an epothilone B analog, which induces
microtubule stabilization [13]. It is indicated for treatment of
locally advanced or MBC after failure of an anthracycline, a
taxane, and capecitabine, or combined with capecitabine
following anthracycline and taxane failure [14]. Ixabeplione
has been investigated in three Phase II monotherapy studies
[15–17] and included as a comparator in a Phase III study
[18] involving patients with MBC. In two of the Phase II
studies (ixabepilone in patients with MBC resistant to either
a taxane [15] or an anthracycline, a taxane, and capecitabine
[16]), 60–63 % of patients reported sensory PN (all grades);
motor neuropathy was reported by 2–10 % of patients and
Grade 3/4 events reported by 12–13 % of patients [15, 16]. In
the third Phase II study, ixabepilone was administered as
first-line therapy in taxane-naı¨ve patients with MBC previ-
ously treated with an adjuvant anthracycline. Treatment with
ixabepilone was associated with an incidence of sensory PN
of 71 % (all grades) and 20 % (Grade 3; no Grade 4), and of
motor neuropathy of 6 % (5 % Grade 3; no Grade 4) [17]. In
the Phase III study comparing paclitaxel, nanoparticle
albumin-bound paclitaxel, and ixabepilone, with or without
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bevacizumab, as first-line therapy for MBC, CGrade 2 sen-
sory PN was reported for 44 % of patients treated with ix-
abepilone [18].
While these reports highlight that incidences of che-
motherapy-induced PN differs between conventional
agents, the precise underlying cellular mechanisms are
unclear. In preclinical studies using mouse models of
neuropathy, paclitaxel and ixabepilone at their equivalent
maximum tolerated doses produced deficits in nerve con-
duction parameters and caused degenerative pathological
changes, whereas eribulin did not affect conduction and
caused milder, less frequent effects on cell morphology
[19]. In in vitro studies, inhibition of microtubule-depen-
dent axonal transport was reduced with eribulin compared
with paclitaxel, ixabepilone, and vincristine [20]. These
results suggest that eribulin may have lesser clinical impact
upon nerve function and morphology than other tubulin-
targeting agents.
This Phase II, randomized study assessed the incidence
and severity of neuropathy adverse events (AEs) in patients
with locally recurrent or MBC after treatment with either
eribulin or ixabepilone. Overall safety, tolerability, and
efficacy profiles were also examined.
Methods
Study design
This Phase II, multicenter, randomized, open label study
(Study E7389-G000-209; NCT00879086) recruited
patients with locally recurrent or MBC who had received
prior taxane therapy, at least one prior cytotoxic chemo-
therapy for advanced disease, and progressed during or
after their last anti-cancer therapy. Patients were enrolled at
48 sites in the United States.
Patients were pre-stratified based on pre-existing
neuropathy (National Cancer Institute Common Termi-
nology Criteria for Adverse Events version 3.0 [CTCAE]
Grade 0 or 1) and number of prior chemotherapies (B3 or
[3). Patients were then randomized (1:1) to eribulin or
ixabepilone treatment groups in a consecutive sequence.
All patients provided written informed consent. The
study was conducted in accordance with the International
Conference on Harmonization Guidelines for Good Clini-
cal Practice, the Declaration of Helsinki, and the institu-
tional review board/ethics committee at each site.
Study objectives
The primary objective was to assess the incidence of
neuropathy AEs in patients treated with eribulin or ixab-
epilone, graded using the CTCAE. Neuropathy was based
on a broad list of preferred terms for neuropathy and the
following additional preferred terms: neuropathy, hyper-
esthesia, painful response to normal stimuli, pallanesthesia,
and allodynia. As a sensitivity analysis, analysis of neu-
ropathy was also performed based on a narrow definition of
PN (combined term), including the following preferred
terms: neuropathy peripheral, peripheral motor neuropathy,
polyneuropathy, peripheral sensory neuropathy, peripheral
sensorimotor neuropathy, demyelinating polyneuropathy,
and paresthesia. The secondary safety objectives included:
comparison of severity of neuropathy AEs (defined as for
the primary objective), patient-reported neurotoxicity
questionnaire (PNQ), and vibration sensitivity (vibration
perception threshold [VPT]); time to onset and resolution
of neuropathy; and overall safety and tolerability. Sec-
ondary efficacy objectives were objective response rate
(ORR), clinical benefit rate (CBR), progression-free sur-
vival (PFS), and disease control rate (DCR).
Patients
Key inclusion criteria were: women at least 18 years old
with histologically or cytologically confirmed carcinoma of
the breast (locally recurrent or metastatic); prior taxane
therapy and at least one prior cytotoxic chemotherapy for
locally recurrent or MBC; disease progression during or
after last anti-cancer therapy; pre-existing neuropathy
\Grade 2; Eastern Cooperative Oncology Group perfor-
mance status of 0–2; adequate renal, liver, and bone mar-
row function. Patients must have shown resolution of all
prior chemotherapy or radiation-related toxicities to Grade
B1, except for alopecia, and the ability to complete the
PNQ without assistance from study-site personnel.
Exclusion criteria included: prior ixabepilone or eribulin
therapy; a history of diabetes mellitus concurrent diseases
or conditions expected to interfere with neuropathy
assessments; and significant cardiovascular impairment.
Treatment
Eribulin mesylate 1.4 mg/m2 (equivalent to eribulin
1.23 mg/m2 [expressed as free base]) was administered
intravenously over 2–5 min on days 1 and 8 of each 21-day
cycle, and ixabepilone (starting dose 32 or 40 mg/m2 as per
approved labeling) as a 3-h intravenous infusion on day 1
of each 21-day cycle. A reduced dose of ixabepilone at 32
or 20 mg/m2 was allowed for patients with mild or mod-
erate hepatic impairment, respectively, according to
approved labeling [14].
Treatment continued until unacceptable toxicity, progres-
sion of disease, or the investigator considered that discontin-
uation of therapy was in the patient’s best interest. Dose delays
and modifications were permitted to manage toxicities.
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Concomitant medication
Any medication considered necessary for the patient’s
welfare that was not expected to interfere with the evalu-
ation of either study drug was permitted at the investiga-
tor’s discretion. Palliative radiotherapy was permitted if the
irradiated area involved \10 % of the bone marrow and
was not to be used for tumor response assessment. Study
treatment was delayed during palliative radiotherapy.
Strong CYP3A4 inhibitors, other investigational drugs, and
other anti-tumor therapies were prohibited during the
study; mild or moderate CYP3A4 inhibitors, strong
CYP3A4 inducers, and CYP3A4 substrates were adminis-
tered with caution.
Safety
AEs were graded using CTCAE and coded according to the
Medical Dictionary for Regulatory Activities. AEs reported
here were considered treatment-emergent, i.e., they com-
menced on or after day 1 of cycle 1, and/or increased in
severity during the trial, or had an onset date within
30 days after the last dose of study drug.
Neuropathy assessments (PNQ and VPT) were per-
formed at baseline and on day 1 of cycles 2–6, at the
beginning of every third cycle thereafter, and at the end of
treatment and post-treatment follow-up visits (21 and
42 days after the last dose, respectively). PNQ consisted of
three items (sensory, motor, and composite). VPT was
measured on the ventral surface of the distal index finger
(contralateral to the side of mastectomy or primary disease)
and on the distal pad of the right and left great toes, using a
Vibratron II device (Physitemp, Inc., Clifton, NJ, USA).
Time to onset of neuropathy was defined as number of
weeks from first dose of study treatment to onset of the
earliest neuropathy of CTCAE grade greater than baseline
for that patient. Time to resolution of neuropathy was defined
as number of weeks from last dose of study treatment to the
earliest date of resolution of neuropathy (neuropathy that had
stopped or resolved to either the level at baseline or lower,
and after which there was no further onset).
Efficacy
Tumor assessments performed at screening/baseline and
between days 15 and 21 of cycles 2, 4, and 6 included:
computed tomography (CT) scans of the chest, abdomen,
and pelvis; a bone scan and/or clinical assessments/pho-
tographs of skin lesions; and CT/magnetic resonance
imaging scans. In the extension phase, tumor assessments
were performed every three cycles until progressive dis-
ease (PD) developed.
Tumor response was assessed according to modified
Response Evaluation Criteria in Solid Tumors version 1.0,
and classified as complete response, partial response (PR),
stable disease, or PD. PFS was defined as time from ran-
domization until PD or death due to any cause.
Statistics
The intent-to-treat population consisted of all randomized
patients, and the safety population comprised all patients
who received at least one dose of study medication and had
at least one post-dose safety assessment. A sample size of
49 patients per group was required to detect a significant
difference in the incidence of neuropathy between treat-
ments with 80 % power, at a proportion of 0.35 in the
eribulin group to 0.63 in the ixabepilone group (odds ratio
0.316), at the 0.05 two-sided significance level.
The primary safety endpoint was analyzed using the
Cochran–Mantel–Haenszel test, sensory and motor PNQ
scores were analyzed separately using a generalized linear
model, and hand and foot VPT data were evaluated by
regression analysis. Other neuropathy-related endpoints
were not tested for statistical significance. ORR, DCR, and
CBR were analyzed using the Clopper-Pearson method,
and PFS estimated using Kaplan–Meier analysis.
Results
Patients
In the intent-to-treat population, 104 patients were randomized
equally between the eribulin and ixabepilone groups. The
safety analysis set included 101 patients (Fig. 1; Table 1).
32.7 % of patients had received more than three chemotherapy
regimens prior to entry. Among those patients with pre-exist-
ing neuropathy, the use of medications aimed at symptomatic
management of neuropathy during the course of the study was
balanced between the two treatment groups (4 vs. 3 patients).
Study drug exposure
For the eribulin group, patients received a median number
of 5.0 treatment cycles (range 1–30) and spent a median of
15 weeks on treatment (range 3–92) (Table 2). Ixapebi-
lone-treated patients received a median of 3.5 treatment
cycles (range 1–15) over a median of 10.5 weeks (range
3–49). The relative dose intensities were similar between
the two groups (Table 2). Fewer patients receiving eribulin
required dose reductions compared to ixabepilone (21.6 vs.
32.0 %), although fewer patients receiving ixabepilone
experienced dose omissions, delays, or interruptions com-
pared with those receiving eribulin (Table 2).
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Safety
Neuropathy AEs by CTCAE grade
Neuropathy of any grade was reported by 17 (33.3 %)
and 24 (48.0 %) patients receiving eribulin and ixabepi-
lone, respectively (Table 3). Sensitivity analysis based on
a narrow definition of PN also showed a lower incidence
of PN in the eribulin group (16 patients, 31.4 %) com-
pared with ixabepilone (22 patients, 44.0 %) (Table 3).
After controlling for baseline pre-existing neuropathy
(Grade 0 or 1) and number of prior chemotherapies (B3,
[3) as binary variables, the difference between treat-
ments in overall incidence of neuropathy and PN was not
significant for either (p = 0.1284 and p = 0.1632,
respectively).
Five (9.8 %) and 11 (22.0 %) eribulin- and ixabepilone-
treated patients, respectively, experienced Grade 3 neu-
ropathy. No Grade 4 neuropathy was reported in either
group (Table 3). Sensitivity analysis showed a similar
incidence of Grade 3 PN (5 [9.8 %] vs. 10 [20.0 %] in
patients receiving eribulin and ixabepilone, respectively),
with no Grade 4 events reported (Table 3).
Neuropathy AEs by PNQ and vibration sensitivity
No significant differences were observed in change from base-
line to worst post-baseline score for motor, sensory, or com-
posite PNQ items between the eribulin and ixabepilone groups.
For vibration sensitivity measurements, the starting
threshold values for both the great toe and the index finger
were slightly higher (greater deficit) for the ixabepilone
group, and the degree of on-study deterioration in sensory
function was slightly higher in the eribulin group. How-
ever, there were no significant differences in the pattern of
VPT findings across treatment groups (Fig. 2).
Time to onset and resolution of neuropathy
The onset of neuropathy occurred earlier in ixabepilone-
treated patients than for those receiving eribulin, with a
median time to onset of 11.6 and 35.9 weeks, respectively,
from the start of treatment (Fig. 3). By cycle 4, 24.2 % of
patients receiving eribulin experienced neuropathy compared
with 44.0 % receiving ixabepilone. There were 19 and 12
patients with neuropathy on or after the day of last treatment in
the ixabepilone and eribulin groups, respectively, and the
Fig. 1 CONSORT diagram
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maximum time to resolution of neuropathy was shorter for
patients treated with ixapebilone (n = 19; 10.1 weeks; cen-
sored) than eribulin (n = 12; 48.4 weeks; censored).
Adverse events
The incidences of other AEs were generally comparable
between eribulin- and ixabepilone-treated patients
(Table 4). The most common AEs reported were neutro-
penia (47.1 %), nausea (45.1 %), and alopecia (39.2 %) for
eribulin, and fatigue/asthenia (58.0 %), nausea (54.0 %),
and PN (46.0 %) for ixabepilone (Table 4). A total of 98.0
and 96.0 % of eribulin- and ixabepilone-treated patients,
respectively, experienced AEs that were considered related
to study drug; of these, 60.8 and 64.0 %, respectively, were
graded as 3 or higher. Compared with ixabepilone, fewer
Table 1 Patient demographics and baseline characteristics (safety population)
Eribulin (n = 51) Ixabepilone (n = 50) Total (n = 101)
Age (years) [mean (standard deviation)] 52.2 (9.83) 56.9 (10.68) 54.5 (10.49)
Race, n (%)
White 35 (68.6) 44 (88.0) 79 (78.2)
Black or African-American 13 (25.5) 5 (10.0) 18 (17.8)
Asian 0 1 (2.0) 1 (1.0)
Other 3 (5.9) 0 3 (3.0)
Time since original diagnosis (years) [mean (standard deviation)] 6.7 (5.4) 7.9 (5.6) 7.3 (5.5)
ECOG performance status, n (%)
0 21 (41.2) 20 (40.0) 41 (40.6)
1 29 (56.9) 28 (56.0) 57 (56.4)
2 1 (2.0) 2 (4.0) 3 (3.0)
Pre-existing neuropathy, n (%)
CTCAE Grade 0 24 (47.1) 25 (50.0) 49 (48.5)
CTCAE Grade 1 27 (52.9) 25 (50.0) 52 (51.5)
Hormone receptor status, n (%)
ER positive 37 (72.5) 31 (62.0) 68 (67.3)
PgR positive 27 (52.9) 24 (48.0) 51 (50.5)
Hormone receptor positive 37 (72.5) 32 (64.0) 69 (68.3)
HER2 statusa, n (%)
HER2 positive 4 (7.8) 7 (14.0) 11 (10.9)
Triple negative status (HER2, ER, and PgR negative) 4 (7.8) 11 (22.0) 15 (14.9)
Number of previous chemotherapy regimens in any setting, n (%)
B3 37 (72.5) 31 (62.0) 68 (67.3)
[3 14 (27.5) 19 (38.0) 33 (32.7)
Previous chemotherapy, n (%)b
Taxanes
Paclitaxel 38 (74.5) 42 (84.0) 80 (79.2)
Docetaxel 25 (49.0) 28 (56.0) 53 (52.5)
Paclitaxel and docetaxel 20 (40.0) 12 (23.5) 32 (31.7)
Doxorubicin 41 (80.4) 37 (74.0) 78 (77.2)
Cyclophosphamide 40 (78.4) 36 (72.0) 76 (75.2)
Capecitabine 29 (56.9) 33 (66.0) 62 (61.4)
Gemcitabine 17 (33.3) 21 (42.0) 38 (37.6)
Vinorelbine 14 (27.5) 15 (30.0) 29 (28.7)
Carboplatin 14 (27.5) 14 (28.0) 28 (27.7)
Safety population: all patients who received at least one dose of study medication and had at least one post-dose safety assessment
CTCAE Common Terminology Criteria for Adverse Events, ECOG Eastern Cooperative Oncology Group, ER estrogen receptor, HER2 human
epidermal growth factor receptor 2, PgR progesterone receptor
a Based on fluorescence in situ hybridization (FISH) or immunochemistry in the absence of FISH testing
b The most frequently reported—incidence C22 % in one or more treatment groups
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patients receiving eribulin discontinued treatment due to
neuropathy (3.9 vs. 18.0 %, respectively) or AEs in general
(11.8 vs. 32.0 %). Two patients in each group died during
the study, all secondary to PD.
Efficacy
Best overall responses for patients receiving eribulin or
ixabepilone are shown in Table 5, and Fig. 4 shows
waterfall graphs depicting the change in summed longest
diameter of target lesions from baseline to nadir in eribulin-
and ixabepilone-treated patients. The ORR for eribulin was
15.4 and 5.8 % for ixabepilone (Table 5). Median PFS was
104 days for eribulin-treated patients and 95 days for those
receiving ixabepilone.
Discussion
This is the first clinical study to directly compare
neuropathy, safety, and efficacy of eribulin and ixabepilone
in patients with MBC. The overall incidences of neuropa-
thy and PN were 33.3 versus 48.0 % and 31.4 versus
44.0 % for eribulin versus ixabepilone, respectively.
Regardless of baseline pre-existing neuropathy (Grade 0 or
1) and the number of prior chemotherapies (B3,[3), these
differences were not significant. The original sample size
calculation for the study, to detect a 28 % difference in
neuropathy with a power of 80 %, was based on historical
estimates on the incidence of neuropathy with the two
treatments (incidence rates of CTCAE neuropathy events
for eribulin [35 %] as per a previous Phase II study [12],
and the package insert for ixabepilone [63 %]). The
aforementioned results should, therefore, be interpreted
with consideration to the fact that the study was not suf-
ficiently powered to detect the observed magnitude of
difference between the two treatment arms.
The severity of neuropathy AEs according to grade
supported the overall incidence results, with fewer eribulin-
treated patients reporting Grade 3/4 neuropathy or PN.
There were no significant between-group differences in
post-baseline PNQ scores and baseline to worst post-
baseline PNQ scores. Additionally, there was no significant
effect of time (cycles 2 through 6 or overall) on the cor-
relation between the maximum treatment-emergent motor
neuropathy CTC grade and worst post-baseline motor PNQ
score. Although the degree of on-study deterioration in
sensory function was slightly higher with eribulin, these
differences in the pattern of VPT findings across treatment
groups were not clinically meaningful or significant. The
findings in this study must be tempered by the small
number of patients in each group, especially at cycle 6, and
by the substantial variance in the calculated change in VPT
scores across patients.
Table 2 Study drug exposure (safety population)
Eribulin (n = 51) Ixabepilone
(n = 50)
Number of cycles received
Mean (standard deviation) 6.2 (5.6) 4.8 (3.7)
Median (range) 5.0 (1.0–30.0) 3.5 (1.0–15.0)
Weeks on study medication
Mean (standard deviation) 19.8 (18.0) 15.0 (11.6)
Median (range) 15.0 (3.0–92.0) 10.5 (3.0–49.0)
Relative dose intensity (%)
Mean (standard deviation) 85.0 (16.3) 91.2 (11.0)
Median (range) 92.3 (41.6–103.6) 96.3 (49.5–102.5)
Dose omissions, n (%) 9 (17.6) 3 (6.0)
Dose reductions, n (%) 11 (21.6) 16 (32.0)
Dose delays, n (%) 29 (56.9) 17 (34.0)
Dose interruptions, n (%) 6 (11.8) 1 (2.0)
Safety population: all patients who received at least one dose of study
medication and had at least one post-dose safety assessment
Table 3 Incidence of neuropathy and sensitivity analysis of neu-
ropathy based on a narrow definition of peripheral neuropathy by
CTCAE grade (safety population)
Eribulin
(n = 51), n (%)
Ixabepilone
(n = 50), n (%)
Neuropathya
All grades 17 (33.3) 24 (48.0)
Grade 1/2 12 (23.5) 13 (26.0)
Grade 3 5 (9.8) 11 (22.0)
Grade C4 0 0
Peripheral neuropathyb
All grades 16 (31.4) 22 (44.0)
Grade 1/2 11 (21.6) 12 (24.0)
Grade 3 5 (9.8) 10 (20.0)
Grade C4 0 0
Safety population: all patients who received at least one dose of study
medication and had at least one post-dose safety assessment
CTCAE Common Terminology Criteria for Adverse Events, MedDRA
Medical Dictionary for Regulatory Activities
a Combined MedDRA preferred term based on a broad list of pre-
ferred terms defined in standardized MedDRA queries for neuropathy
and the following additional preferred terms: neuropathy, hyperes-
thesia, painful response to normal stimuli, pallanesthesia, and allo-
dynia. If a combined term had[1 CTC grade, the highest CTC grade
was used
b Of those patients with neuropathy (combined term), peripheral
neuropathy was based on a narrow list of preferred terms defined in
standardized MedDRA queries for neuropathy and included: neu-
ropathy peripheral, peripheral motor neuropathy, polyneuropathy,
peripheral sensory neuropathy, peripheral sensorimotor neuropathy,
demyelinating polyneuropathy, and paresthesia
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Eribulin was associated with a longer time to onset of
neuropathy in this study. Resolution of neuropathy (in
patients with existent neuropathy at the time of treatment
discontinuation) tended to occur relatively sooner in
patients receiving ixabepilone. However, patients receiving
eribulin achieved a greater median number of treatment
Fig. 2 Vibration perception
threshold scores at baseline, and
change from baseline at cycle 3
and 6 in patients receiving
eribulin or ixabepilone (safety
population)
Fig. 3 Kaplan–Meier analyses
of time to onset of neuropathy
with eribulin and ixabepilone
(safety population)
Table 4 Adverse events with an incidence of [20 % (safety population)
Eribulin (n = 51), n (%) Ixabepilone (n = 50), n (%)
All grades Grade 3 Grade 4 All grades Grade 3 Grade 4
Neutropenia 24 (47.1) 8 (15.7) 8 (15.7) 14 (28.0) 5 (10.0) 5 (10.0)
Nausea 23 (45.1) 0 0 27 (54.0) 1 (2.0) 0
Alopecia 20 (39.2) 0 0 21 (42.0) 0 0
Fatigue/astheniaa 19 (37.3) 2 (3.9) 0 29 (58.0) 6 (12.0) 1 (2.0)
Peripheral neuropathya 18 (35.3) 5 (9.8) 0 23 (46.0) 10 (20.0) 0
Decreased appetite 17 (33.3) 1 (2.0) 0 13 (26.0) 1 (2.0) 0
Myalgia/arthralgiaa 14 (27.5) 2 (3.9) 0 22 (44.0) 5 (10.0) 1 (2.0)
Anemia 13 (25.5) 3 (5.9) 0 10 (20.0) 3 (6.0) 0
Diarrhea 12 (23.5) 0 0 12 (24.0) 0 0
Vomiting 12 (23.5) 0 0 15 (30.0) 1 (2.0) 0
Constipation 11 (21.6) 1 (2.0) 0 10 (20.0) 0 0
Mucosal inflammation 11 (21.6) 0 1 (2.0) 1 (2.0) 1 (2.0) 0
Dyspnea 6 (11.8) 1 (2.0) 0 13 (26.0) 2 (4.0) 0
Safety population: all patients who received at least one dose of study medication and had at least one post-dose safety assessment
a Combined Medical Dictionary for Regulatory Activities (MedDRA) terms
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cycles and remained on treatment for longer than those
receiving ixabepilone. This raises the possibility that the
observed longer time to resolution of neuropathy in
patients with ongoing neuropathy at the time of treatment
discontinuation in the eribulin group could be attributed to
treatment for a longer period than those receiving ixab-
epilone. A recent pooled analysis of five ixabepilone
studies in patients with MBC suggested that PN associated
with this agent is cumulative, as the incidence of Grade 3/4
events was shown to increase with median cumulative ix-
abepilone dose [21]. In addition, PN associated with ix-
abepilone was shown in monotherapy studies to be
generally reversible and often manageable with dose
reduction [15–17]. In one such trial, Grade 3/4 PN resolved
in 76 % of patients, with a median time to resolution of
5.4 weeks [16]. In EMBRACE, time to onset or resolution
of neuropathy were not examined; however, patients with
Grade 3/4 PN who continued eribulin treatment also
showed improvement following dose modification [7].
In the current study, both agents demonstrated man-
ageable safety profiles. Eribulin exhibited fewer
neuropathy-related treatment discontinuations than ixab-
epilone (3.9 vs. 18.0 %), which is in line with previously
Table 5 Best overall responses and overall response, clinical benefit,
and disease control rates with eribulin and ixabepilone (intent-to-treat
population)
Eribulin (n = 52),
n (%)
Ixabepilone
(n = 52), n (%)
Best overall response
CR 0 0
PR 8 (15.4) 3 (5.8)
SD 27 (51.9) 26 (50.0)
PD 10 (19.2) 11 (21.2)
Not evaluable 7 (13.5) 12 (23.1)
ORR (95 % CI) 8 (15.4) (6.9–28.1) 3 (5.8) (1.2–15.9)
CBR (95 % CI) 14 (26.9) (15.6–41.0) 10 (19.2) (9.6–32.5)
DCR (95 % CI) 35 (67.3) (52.9–79.7) 29 (55.8) (41.3–69.5)
Median PFS, days
(95 % CI)
104 (80.0–129.0) 95 (73.0–186.0)
Intent-to-treat population: all randomized patients
ORR was defined as CR ? PR divided by the number of patients in
the intent-to-treat population; CBR was defined as CR ? PR ? SD
C 6 months; and DCR was CR ? PR ? SD
CBRclinicalbenefit rate,CIconfidence interval,CRcomplete response,DCR
disease control rate, ORR objective response rate, PD progressive disease,
PFS progression-free survival, PR partial response, SD stable disease
A
B
Fig. 4 Waterfall graphs of
change in summed longest
diameter of target lesions from
baseline to nadir in A eribulin-
and B ixabepilone-treated
patients
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reported trials. In EMBRACE, treatment discontinuation
due to PN occurred in 5 % of patients in the eribulin group
[7], whereas monotherapy studies of ixabepilone have
reported discontinuations due to neuropathy ranging from 6
to 28 % of patients [15–17]. Discontinuation from treat-
ment due to any toxicity (including neuropathy) was also
lower with eribulin than ixabepilone (11.8 vs. 32.0 %).
Due to the small sample size, formal statistical analyses
were not planned in the study. In addition, a considerable
proportion of patients being either censored or deemed
‘‘non evaluable’’ for efficacy assessments precluded any
robust efficacy interpretations from the study. Eribulin,
however, had a more favorable impact on ORR than ix-
abepilone (15.4 vs. 5.8 %, respectively) due to a higher
proportion of patients exhibiting PRs. In the current study,
tumor responses observed with eribulin are similar to those
in three previous reports, each of which included patients
who had received a median of four previous chemothera-
pies: in the two earlier Phase II studies of eribulin, ORRs
were 9.3 % (95 % CI 6.1–13.4) and 11.5 % (95 % CI
5.7–20.1) [11, 12]; and in EMBRACE, a significantly
higher ORR was reported for eribulin (12 % [95 % CI
9.4–15.5]) compared with TPC (5 % [95 % CI 2.3–8.4];
p = 0.002) [7]. With the median PFS being numerically
similar in the eribulin group compared with the ixabepilone
group (3.4 vs. 3.1 months, respectively), no clinically
meaningful differences in PFS between eribulin and ixab-
epilone were observed.
In conclusion, differences in the overall incidence of
neuropathy were not statistically significant even after
controlling for baseline pre-existing neuropathy (Grade 0
or 1) and number of prior chemotherapies (B3,[3). Small
sample size and lack of power in the study to detect the
observed magnitude of differences may explain why there
was no significant numerical differences in the primary
safety endpoint between eribulin and ixabepilone. Time to
onset of neuropathy tended to occur later and resolve later
with eribulin compared with ixabepilone, possibly because
patients in the eribulin group received a greater number of
treatment cycles and remained on treatment for longer than
those in the ixabepilone group. Compared with ixabepi-
lone, fewer patients receiving eribulin discontinued treat-
ment due to neuropathy or AEs in general. Additional
studies may be required to confirm whether patients may
derive significant benefits with eribulin over ixabepilone
with respect to the neuropathy profile.
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